The associations of candidate gene polymorphisms with aspirin resistance in patients with ischemic disease: a meta-analysis Authors: Chun-xing Li, Li-chaoyue Sun, Yu-qiao Wang, Tian-tian Liu, Jin-rui Cai, Hua Liu, Zhao Ren, Zhanmiao Yi Published: 2024 ABSTRACT BackgroundRecently, extensive research has been conducted on the relationship between aspirin gene polymorphisms and aspirin resistance (AR) in patients with ischemic diseases. Among the numerous candidate genes, it remains unclear which ones are significantly associated with AR and could potentially serve as potential biomarkers for genetic testing before aspirin use.MethodsEligible articles were searched in PubMed, Embase, Cochrane Library, WanFang, CNKI and Sinomed. A cohort study examining the efficacy of aspirin in secondary prevention for patients with ischemic diseases, along with a discussion on genetic polymorphisms and their association with AR, has been included. The Newcastle-Ottawa Scale for assessing the quality of included studies. Odds ratios (OR) with 95% confidence intervals (CI) were used as measures of effect. Subgroup analyses were conducted based on different genotypes with the same genetic polymorphisms, different research regions and types of ischemic diseases.ResultsFrom 75 eligible articles, 94 candidate gene polymorphisms were analyzed. In the overall analysis, 25 genes were subjected to meta-analysis and 69 genes were systematically described. 23 gene polymorphisms were observed to be significantly associated with AR, including PTGS2(rs20417) (OR = 0.57, 95% CI: 0.44–0.73), ITGA2(rs1126643) (OR = 0.52, 95% CI: 0.29–0.93), and TbXA2R(rs1131882) (OR = 1.54, 95% CI: 1.09–2.18) were obtained from the combined analysis of this study, and 20 genes were systematically described in this study. Further subgroup analyses demonstrated that AA genotype for PTGS1(rs1330344) (OR = 0.56, 95%CI:0.43–0.74), C allele for PTGS1(rs5788) (OR = 0.51, 95%CI: 0.30–0.87) polymorphisms were significantly associated with AR. The polymorphisms of 13 genes, including PTGS1(rs1236913), have been studied only in Asia, GP6(rs1613662) has been studied only in Europe, and the polymorphisms of 5 genes, including ABCB1(rs1045642), showed different correlations with AR in various regions. The individuals with the PTGS1 (rs5788) variant who experienced an ischemic stroke (OR = 0.98, 95%CI: 0.54–1.67) may exhibit an elevated risk of AR compared to those with coronary artery disease (OR = 0.51, 95%CI: 0.3–0.87).ConclusionsOur meta-analysis indicates that PTGS2(rs20417), ITGA2(rs1126643), and TbXA2R(rs1131882) could be potential genetic biomarkers for AR. Among these, PTGS2 (rs20417) is particularly suggested for individuals in Asia with ischemic diseases before aspirin use, as the GC/CC genotype raises AR risk by 42% compared to GG. ITGA2 (rs1126643) increases AR risk by 48% in Asia with the TC/TC genotype versus CC. However, results for ABCB1(rs1045642) and GP1BA(rs2243093) vary by regions, requiring further research.Supplementary InformationThe online version contains supplementary material available at 10.1186/s40246-024-00699-1. Introduction Cardiovascular and cerebrovascular diseases are the leading cause of disability and mortality in the world [1]. Aspirin remains the gold standard in antiplatelet therapy for preventing recurrent adverse cardiovascular events in patients with atherosclerotic disease, and it is consistently the most frequently prescribed antiplatelet medication [2]. It has been established that regular use of aspirin 75–100 mg/day was adequate to induce favorable preventive effects against cardiovascular events [3–5]. Nevertheless, due to significant individual variations in responsiveness to aspirin, a considerable proportion of patients may not derive the full benefits of this anti-platelet medication [6]. Despite the regular intake of aspirin, patients may not attain the expected anti-thrombotic efficacy, thereby increasing their susceptibility to severe cardiovascular events. This phenomenon is known as ‘aspirin resistance’ (AR) or ‘high on-aspirin platelet reactivity’ [6–9]. AR is divided into laboratory aspirin resistance (LAR) and clinical aspirin resistance (CAR). Generally, LAR refers to insufficient inhibition of thromboxane A2 (TXA2) or failure to reduce platelet aggregation; this leads to an increase in TXA2 metabolites in urine and plasma, CAR is defined as the failure to prevent thrombotic events in patients [10]. A comprehensive meta-analysis, encompassing 65 studies, showed that 24.7% of cardiovascular disease patients had LAR. Prevalence was 27.3% in Asia, 25.7% in Europe, 19.5% in Africa, and 19.1% in America. Women had a slightly higher risk of AR than men, with an odds ratio (OR) of 1.16 [11]. Recent research indicates that individuals with AR face nearly triple the risk of adverse cardiovascular events compared to those who are aspirin sensitive [12]. Similarly, Krasopoulos et al. have reported an OR of approximately 6.0 for heightened mortality among patients with resistant vascular disease [13]. Therefore, it is particularly important to find the causes of AR and identify the risk factors for AR. The mechanism of AR is not fully understood. It is likely influenced by a variety of factors. Studies have identified particular single nucleotide polymorphisms (SNPs) that are strongly associated with AR, suggesting that genetic influences account for roughly 30% of platelet reactivity [14]. Genetic variations in a number of platelet receptors, their major ligands or key mediators of platelet effect or mechanisms, can influence the response of platelets to Aspirin [15]. Cyclooxygenase (COX) is a key enzyme in the pathways of prostaglandins, thromboxanes, and prostacyclins. There are two COX isoenzymes, namely COX-1 and COX-2, also known as prostaglandin-endoperoxide synthase 1 (PTGS1) and PTGS2, respectively [16]. Aspirin inhibits platelets by irreversibly blocking COX-1, specifically through acetylation of serine 529 in the enzyme’s active site, thereby greatly decreasing TXA2 production [17]. A study in the Chinese Han population revealed that PTGS1 polymorphism was independently associated with the recurrent ischemic stroke [18]. Another study found that among Chinese ischemic stroke patients treated with aspirin, four alleles (rs1330344, rs10306114, rs3842788, and rs5788) were identified in PTGS1, with rs1330344 significantly associated with vascular events. PTGS2 polymorphisms are also closely related to thrombosis and inflammation [19]. GP IIb/IIIa, an integrin complex on platelets, consists of subunits from ITGA2B and ITGB3 genes. Genetic variations in these genes can affect how individuals respond to aspirin and may increase the risk of thrombotic events [20]. GP Ia/IIa and GP VI are important collagen receptors. GP Ia/IIa, encoded by ITGA2 and ITGB1, initiates platelet-collagen interaction and activates platelets via GP VI. Variants of GP Ia/IIa and GP VI may affect aspirin’s antiplatelet effect [21]. The ITGA2(rs1126643) polymorphism has been linked to AR in some studies [22, 23], but a recent meta-analysis found no direct link between this variant and CAD or myocardial infarction [24]. P2Y1 and P2Y12 are G protein-coupled receptors mainly on platelet surfaces, encoded by P2RY1 and P2RY12 genes. Research indicates that the P2RY1(rs1065776) gene may reduce aspirin’s effects in healthy volunteers [25]. The TXA2 Receptor, encoded by TBXA2R, is widely distributed and SNPs in its gene can influence the risk of cerebral ischemia and platelet function, particularly platelet aggregation [26]. Aspirin and platelet activation involve multiple targets, with genetic variations potentially causing AR. Research has explored various candidate genes [17–26], but it’s unclear which genetic polymorphisms are clinically significant and could become potential biomarkers. The Clinical Pharmacogenetics Implementation Consortium guidelines support testing for certain drugs but not aspirin, due to insufficient evidence [27–30]. Therefore, we performed a meta-analysis of all published genetic association studies to assess the association between candidate gene polymorphisms and AR in patients with coronary heart disease and ischemic stroke from cohort studies using meta-analysis. Methods Literature search and inclusion criteria This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement [31]. The study’s methodology was officially registered with the International Prospective Register of Systematic Review (PROSPERO), bearing the registration number CRD42022381899. A systematic literature search was conducted across PubMed, Embase, Cochrane Library, Wanfang Med online (http://med.wanfangdata.com.cn/), China National Knowledge Internet (CNKI) (https://www.cnki.net/) and Chinese biomedical literature service system (SinoMed) (http://www.sinomed.ac.cn/index.jsp). The search encompassed articles published in English or Chinese language from establishment to May 31st, 2024. The search strategy focused on three distinct groups, integrating a meticulous combination of MeSH terms and text words as follows: Group A, focusing on participants related to “Coronary Disease” or “Stroke”; Group B, centering on genetic polymorphism associated with “Pharmacogenetics”; and Group C, examining aspirin “Aspirin resistance” or “Aspirin insensitivity”). The detailed search strategies are shown in Appendix 2. Two researchers (YQ W and JR C) conducted a comprehensive literature search according to the above search strategies. To identify other potentially relevant publications, we also reviewed the reference lists of all retrieved articles. Study selection and data extraction The Eligibility criteria of this study include: Studies involving adult patients diagnosed with coronary disease or stroke;Studies that include patients treated with aspirin for secondary prevention of ischemic events;Studies that clearly describe aspirin use for at least 7 days at doses ranging from 75 to 300 mg per day;Studies detailing methods to assess the impact of aspirin on platelet reactivity;Studies reporting the occurrence of various genotypes or alleles in aspirin-resistant and sensitive groups. Studies involving adult patients diagnosed with coronary disease or stroke; Studies involving adult patients diagnosed with coronary disease or stroke; Studies that include patients treated with aspirin for secondary prevention of ischemic events; Studies that include patients treated with aspirin for secondary prevention of ischemic events; Studies that clearly describe aspirin use for at least 7 days at doses ranging from 75 to 300 mg per day; Studies that clearly describe aspirin use for at least 7 days at doses ranging from 75 to 300 mg per day; Studies detailing methods to assess the impact of aspirin on platelet reactivity; Studies detailing methods to assess the impact of aspirin on platelet reactivity; Studies reporting the occurrence of various genotypes or alleles in aspirin-resistant and sensitive groups. Studies reporting the occurrence of various genotypes or alleles in aspirin-resistant and sensitive groups. AR is defined as an adenosine diphosphate (ADP)-induced platelet aggregation rate of ≥ 70%, and an arachidonic acid (AA)-induced platelet aggregation rate of ≥ 20%. When one of these results is observed, it is defined as aspirin semi-sensitivity (ASS) or aspirin semi-resistance (ASR), and the remaining cases are referred to as aspirin sensitive (AS) [32]. Studies that meet the criteria above were included to analyze the association between candidate gene polymorphisms and AR. Two independent researchers screened eligible studies using ENDNOTE X9. Following automatic and manual deduplication, all retrieved studies were judged to meet the inclusion criteria by reading the title and abstract. Potentially included studies and conflicted studies required a full-text assessment. Disagreements were resolved through consensus or by involving a third researcher. Data extraction and quality assessment From each included study, the following information was extracted: first author, publication year, race, diagnosis, age, sex, antiplatelet therapy regimen, candidate genotype, sample size and number of events in AR and non-AR groups. The Newcastle-Ottawa Scale (NOS), a well-established quality assessment tool for observational studies, was utilized to evaluate the credibility of the included articles across three dimensions: selection, comparability, and exposure [33]. The NOS has a scoring range from 0 to 9, with studies scoring above 7 considered to be of high quality. Data extraction and quality assessment were independently performed by two reviewers (Wang and Cai). In cases where additional information or original data were required, the reviewers contacted the corresponding authors. Any disagreements between the two reviewers were resolved through discussions with a third reviewer (Li) until a consensus was achieved. Statistical analysis All data analyses in the present study were carried out using STATA software version 16.0 (Stata Corp LP, College Station, TX, USA). The OR and 95% confidence interval (CI) for were calculated using a fixed-effect model with the Mantel-Haenszel method or a random-effect model with the DerSimonian and Laird method according to study heterogeneity. Statistical heterogeneity was assessed by the χ² test and was quantified using the I2 statistic. If I2 > 50%, a random effects model was used for analysis; otherwise, a fixed effects model was used. Sensitive Analysis was conducted to evaluate the stability of the results. Contour-enhanced funnel plot were used to assess potential publication bias. Statistical significance was considered as P < 0.05. AR, ASR, and ASS are all categorized as AR, while AS is categorized as AS. Results Characteristics of included studies The literature review yielded 1,278 citations. Following the elimination of irrelevant or duplicate articles through title and abstract screening, 960 articles were chosen for further evaluation. Ultimately, 75 articles [32, 34–107] were included in our meta-analysis (Fig. 1). All eligible studies were published between 2005 and 2023. A significant majority, 85.33% (64/75), originated from Asia, with 9.33% (7/75) from Europe, and 1.33% (1/75) each from Africa and North America. The study populations predominantly consisted of patients with stroke and coronary heart disease. Regarding age distribution, 18.67% (14/75) of the studies reported an average age range of 50–60 years, 56% (42/75) had an average age range of 60–70 years, and 18.67% (14/75) had an average age exceeding 70 years. The average percentage of male participants was (65.08 ± 12.08)%. The baseline characteristics of the included studies are detailed in Table 1. Fig. 1Flowchart of study selection Flowchart of study selection Table 1The characteristics of included studiesStudyCountryPublication dateStudy designPatientsAge, mean (SD)Male sex (%)Gene polymorphismNo.Patients(AR: AS)OutcomesAbderrazek F 2009Tunisia2010Prospective cohortCAD58.4 ± 9.689.9 ITGB3(rs5918) 81: 107aspirin resistanceAl-Azzam SI 2013Jordan2013Prospective cohortCAD61.6 ± 11.260.8 ITGA2(rs1126643) 92: 492aspirin resistanceCai H 2016China2016Prospective cohortAIS59.5 ± 11.576.3PTGS1(rs1330344, rs3842788, rs5788)128:521aspirin resistanceCao LP 2013China2013Prospective cohortStroke63.2 ± 10.481.2ITGB3(rs5918, rs2317676, rs11871251)429:28aspirin resistanceCao LP 2014China2014Prospective cohortAIS61.2 ± 11.483.1PTGS2(rs20417, rs5275)865:89aspirin resistanceChen JC 2016China2016Prospective cohortAIS67 ± 1161.3 PTGS2(rs20417) 80:233aspirin resistanceChen JJ 2019China2019Prospective cohortIS52.7 ± 14.537.8 PEAR1(rs12041331) 46:102aspirin resistanceChi WZ 2013China2013Prospective cohortAIS69.6 ± 10.351.4 PTGS2(rs20417) 597:157aspirin resistanceClappers N 2008Netherlands2008Prospective cohortCAD63.2 ± 12.465 PTGS1(rs3842787) 98:398aspirin resistanceFan L 2012China2012Prospective cohortIS, CAD74.5 ± 8.366.2 PTGS1(rsl330344) 158:36aspirin resistanceGao F 2011China2011Prospective cohortUnstableCAD64.6 ± 11.363.5 ITGB3(rs5918) 23:235aspirin resistanceGeng L 2013China2013Prospective cohortCAD65 ± 1157.4 SLC6A9(rs2248829) 54:55aspirin resistanceGuan H 2018China2018Prospective cohortMINA57.5 P2C19(rs4244285) 8:82aspirin resistanceGUO S 2020China2020Prospective cohortIS63.1 ± 11.563ABCB1(rs1045642, rs1128503, rs2032582)150:80aspirin resistanceGuo WJ 2016China2016Prospective cohortIS68.2 ± 10.556.7 PTGS2(rs20417) 60:90aspirin resistanceHuang JJ 2013China2013Prospective cohortIS72.3 ± 10.565.4UMPS(rs3772810), PTGS2 (rs20417) P2RY1 (rs1065776)53:66aspirin resistanceHQ 2016China2016Prospective cohortHypertension, CAD, IS,80.1 ± 8.284.3PTGS1(rs3842788, rs5788), PTGS2(rs20417)81:155aspirin resistanceIkonnikova A 2022Russia2022Prospective cohortIS73.2 ± 14.545.9ITGB3(rs5918),GP1BA(rs6065), ABCB1(rs1045642) PTGS1(rs10306114)220:241aspirin resistanceJastrzebska M 2019Poland2019Prospective cohortCAD62.3 ± 8.274.1 ITGB3 PIA1/A2 10:125aspirin resistanceJefferson BK 2005American2005Prospective cohortMI64.5 ± 10100 P2RY1(rs1065776) 95:235aspirin resistanceKıraç D 2022Turkey2022Prospective cohortCAD59.5 ± 10.456.6PTGS1(rs1330344), PTGS2 (rs20417)48:52aspirin resistanceKranzhofer R 2006Germany2006Prospective cohortCADNANA ITGB3(rs5918) 14: 15aspirin resistanceLepäntalo A 2006Finland2006Prospective cohortPCI61(37–83)75.2 PTGS1(rs10306114) 5:96aspirin resistanceLev EI 2007American2007Prospective cohortPCI65.5 ± 10.968.3 ITGB3(rs5918) 12:108aspirin resistanceLi CX 2011China2011Prospective cohortASCVD61 ± 18.454GPIIIaPLA2, SLC6A9(rs2248829)151:8aspirin resistanceLi X 2019China2019Prospective cohortAIS58.1 ± 10.569.4PTGS1(rs1330344), PTGS2(rs20417)25:45aspirin resistanceLi XG 2017China2017Prospective cohortIS60.5 ± 7.391.4CYP2C19, ABCB128:30aspirin resistanceLi XL 2012China2012Prospective cohortCAD, Stroke, PAOD74.8 ± 8.465.7PTGS1(rs1330344, rs3842787), PTGS2(rs5277)36:230aspirin resistanceLiu J 2023China2023Prospective cohortCAD75.3 ± 328.4 GP IIIa PLA 182:33aspirin resistanceLiu QY 2023China2023Prospective cohortAIS59 ± 5.673.1PTGS2(rs12042763, rs20417)87:125aspirin resistanceLiu SB 2021China2021Prospective cohortAIS61.6 ± 13.265.1 PTGS1 8:290aspirin resistanceLiu Y 2021-1China2021Prospective cohortCAD65.3 ± 9.567.3PEAR1(rs12041331), PTGS1(rs1330344),110:230aspirin resistanceLiu Y 2021-2China2021Prospective cohortCAD65.3 ± 963.4 PTGS2(rs20417) 110:230aspirin resistanceMateos-Cáceres PJ 2008Spain2008Prospective cohortIschemic disease66 ± 859 PTGS1(rs3842787) 19: 19aspirin resistanceMou FQ 2013China2013Prospective cohortIS65.1 ± 15.4NA COX-1 709 C/A 13:14aspirin resistanceMukarram O 2016China2016Prospective cohortCAD58.6 ± 10.868.1ITGA2(rs1126643), ITGB3(rs5918), P2RY1 (rs1065776), PTGS1 (rs3842787)8:32aspirin resistancePamukcu B 2005Turkey2005Prospective cohortCAD56.5 ± 8.977.5 ITGB3(rs5918) 43: 161aspirin resistancePeng LL 2014China2014Prospective cohortStroke62.5 ± 12.662.6PTGS1(rs1330344, rs3842788, rs5788), PTGS2 rs2041718: 174aspirin resistancePeng LL 2016China2016Prospective cohortStroke65.1 ± 12.563.2ABCB1(rs1045642), TBXA2R(rs1131882)33:55aspirin resistanceSevimli S 2014Turkey2014Prospective cohortCAD59.8 ± 775.4 -455 G/A b-fibrinogen 25:89aspirin resistanceSu GH 2007China2007Prospective cohortASCVD65.4 ± 8.374.2 SLC6A9(rs2248829) 9:90aspirin resistanceTIMUR AA 2012American2012Prospective cohortMI, PCI65 ± 1082 P2RY12(rs9859538) 99: 313aspirin resistanceUlehlova J 2014Czech Republic2014Prospective cohortMI5171.2PTGS1(rs10306114), GP1BA(rs2243093), GP6(rs1613662)13:115aspirin resistanceWang BY 2012China2012Prospective cohortCAD, IS76.1 ± 3.665.5 PTGS1(rsl330344) 422:250aspirin resistanceWang H 2018China2018Prospective cohortAIS68 ± 1161.2ITGA2(rs1126643), PTGS2 (rs20417)43:54aspirin resistanceWang L 2015China2015Prospective cohortASCVD69.5 ± 13.474.7PTGS1(rs10306114), P2RY1(rs1065776), SLC6A9(rs2248829)28:144aspirin resistanceWang LQ 2022China2022Prospective cohortCAD69 ± 10.350.8 APOE 37:83aspirin resistanceWang LL 2016China2016Prospective cohortCAD, IS63.2 ± 8.657.3ALOX5AP(rs10507391, rs4769874, rs9551963)340:110aspirin resistanceWang LL 2021China2021Prospective cohortIS63.3 ± 11.372 PTGS1 15:85aspirin resistanceWang XJ 2018China2018Prospective cohortPCI52.5 ± 8.458.5 PEAR1(rs12041331) 105:30aspirin resistanceWang YH 2012China2012Prospective cohortCADNANA PTGS1(rs10306114) 150:6aspirin resistanceWang YM 2012China2012Prospective cohortTreat with antithrombotic therapy68.7 ± 14.876.6 PTGS2(rs20417) 151: 54aspirin resistanceWang ZY 2016China2016Prospective cohortIS63 ± 1157.3ABCB1(rs1045642, rs1128503, rs2032582)77:225aspirin resistanceWen SY 2014China2014Prospective cohortliIS62.1 ± 7.162TbXA2R(rs1131882, rs4523), SLC22A3(rs555754)39:129aspirin resistanceWu SY 2022China2022Prospective cohortAIS66.6 ± 10.169.6GP1BA(rs6065), PEAR1(rs12041331), PTGS1(rs3842788), ITGA2B(rs5911), HMOX1(rs2071746)15:77aspirin resistanceXu L 2021China2021Prospective cohortAIS65 ± 1161.3 CYP2S1(rs34971233) 77:225aspirin resistanceXu LX 2017China2017Prospective cohortIS75.2 ± 8.353.6 PTGS1(rs3842787) 36:180aspirin resistanceXu HN 2021China2021Retrospective cohortAIS60.5 ± 6.554.5 PTGS1 69:131aspirin resistanceXu JJ 2016China2016Prospective cohortCAD58 ± 10.578PTGS1(rs3842788, rs4273915 rs7866582, rs3218625)166:200aspirin resistanceXu X 2013China2013Prospective cohortCAD, IS66.4 ± 12.362CYP2D6(rs72549358), PTGS2(rs20417)89:27aspirin resistanceYang R 2009China2009Prospective cohortCAD, IS68.8 ± 15.678.6PTGS1(rs3842788, rs5788), PTGS2(rs20417)71:110aspirin resistanceYang XF 2020China2020Prospective cohortIS71.5 ± 5.862 GP1BA (rs6065) 12:114aspirin resistanceYe P 2012China2012Prospective cohortCAD65 ± 11NAPTGS1, PTGS2273:95aspirin resistanceYi X 2016China2016Prospective cohortAIS70.4 ± 12.153.5PTGS1(rs1236913, rs3842787), PTGS2(rs689466, rs20417)175:630aspirin resistanceYi XY 2013China2013Prospective cohortIS69.5 ± 10.352.4PTGS1(rs3842787), PTGS2(rs20417)157:477aspirin resistanceYi XY 2016China2016Prospective cohortIS69.6 ± 10.552.3PTGS1(rs1236913, rs3842787), PTGS2(rs20417)157:477aspirin resistanceYi XY 2017China2017Prospective cohortAIS71.1 ± 12.651.7PTGS1(rs1236913, rs3842787), PTGS2(rs689466, rs20417), P2RY1(rs701265, rs1371097)112:717aspirin resistanceYurek E 2023Turkey2023Prospective cohortAIS52.4 ± 13.462.8 ABCB1(MDR-1); C3435T(rs1045642) 174:106aspirin resistanceYu LH 2015China2015Prospective cohortIS70.3 ± 8.576.3 GPIIbHPA-3 152:250aspirin resistanceYuan JG 2016China2016Prospective cohortAIS60.2 ± 10.650.8DE4D (rs966221, rs918592)54:129aspirin resistanceZhang J 2009China2009Prospective cohortCAD75.5 ± 8.261.5 PTGS2(rs20417) 176:23aspirin resistanceZhang SS 2015China2015Retrospective cohortIS64.1 ± 11.964.6PTGS1(rs1330344, rs3842788, rs5788), PTGS2(rs20417)9:87aspirin resistanceZhang WT 2017China2017Prospective cohortAIS59.3 ± 14.173.3ITGB3(rs5918), P2RY1(rs701265, rs1065776)31: 175aspirin resistanceZhang R 2019China2019Prospective cohortAIS62.8 ± 9.953.4 PTGS1(rs10306114) 32:268aspirin resistanceZhao Y 2011China2011Prospective cohortASCVD73.1 ± 6.160.5 PTGS2(rs20417) 73:33aspirin resistanceAbbreviations: AS = Aspirin sensitivity; AR = Aspirin resistance; CAD = coronary artery disease; AIS = Atherosclerotic ischemic stroke; IS = ischemic stroke; MI = myocardial infarction; PCI = percutaneous coronary intervention; PAOD = peripheral arterial occlusive disease; ASCVD = atherosclerotic cardiovascular disease Table 1The characteristics of included studiesStudyCountryPublication dateStudy designPatientsAge, mean (SD)Male sex (%)Gene polymorphismNo.Patients(AR: AS)OutcomesAbderrazek F 2009Tunisia2010Prospective cohortCAD58.4 ± 9.689.9 ITGB3(rs5918) 81: 107aspirin resistanceAl-Azzam SI 2013Jordan2013Prospective cohortCAD61.6 ± 11.260.8 ITGA2(rs1126643) 92: 492aspirin resistanceCai H 2016China2016Prospective cohortAIS59.5 ± 11.576.3PTGS1(rs1330344, rs3842788, rs5788)128:521aspirin resistanceCao LP 2013China2013Prospective cohortStroke63.2 ± 10.481.2ITGB3(rs5918, rs2317676, rs11871251)429:28aspirin resistanceCao LP 2014China2014Prospective cohortAIS61.2 ± 11.483.1PTGS2(rs20417, rs5275)865:89aspirin resistanceChen JC 2016China2016Prospective cohortAIS67 ± 1161.3 PTGS2(rs20417) 80:233aspirin resistanceChen JJ 2019China2019Prospective cohortIS52.7 ± 14.537.8 PEAR1(rs12041331) 46:102aspirin resistanceChi WZ 2013China2013Prospective cohortAIS69.6 ± 10.351.4 PTGS2(rs20417) 597:157aspirin resistanceClappers N 2008Netherlands2008Prospective cohortCAD63.2 ± 12.465 PTGS1(rs3842787) 98:398aspirin resistanceFan L 2012China2012Prospective cohortIS, CAD74.5 ± 8.366.2 PTGS1(rsl330344) 158:36aspirin resistanceGao F 2011China2011Prospective cohortUnstableCAD64.6 ± 11.363.5 ITGB3(rs5918) 23:235aspirin resistanceGeng L 2013China2013Prospective cohortCAD65 ± 1157.4 SLC6A9(rs2248829) 54:55aspirin resistanceGuan H 2018China2018Prospective cohortMINA57.5 P2C19(rs4244285) 8:82aspirin resistanceGUO S 2020China2020Prospective cohortIS63.1 ± 11.563ABCB1(rs1045642, rs1128503, rs2032582)150:80aspirin resistanceGuo WJ 2016China2016Prospective cohortIS68.2 ± 10.556.7 PTGS2(rs20417) 60:90aspirin resistanceHuang JJ 2013China2013Prospective cohortIS72.3 ± 10.565.4UMPS(rs3772810), PTGS2 (rs20417) P2RY1 (rs1065776)53:66aspirin resistanceHQ 2016China2016Prospective cohortHypertension, CAD, IS,80.1 ± 8.284.3PTGS1(rs3842788, rs5788), PTGS2(rs20417)81:155aspirin resistanceIkonnikova A 2022Russia2022Prospective cohortIS73.2 ± 14.545.9ITGB3(rs5918),GP1BA(rs6065), ABCB1(rs1045642) PTGS1(rs10306114)220:241aspirin resistanceJastrzebska M 2019Poland2019Prospective cohortCAD62.3 ± 8.274.1 ITGB3 PIA1/A2 10:125aspirin resistanceJefferson BK 2005American2005Prospective cohortMI64.5 ± 10100 P2RY1(rs1065776) 95:235aspirin resistanceKıraç D 2022Turkey2022Prospective cohortCAD59.5 ± 10.456.6PTGS1(rs1330344), PTGS2 (rs20417)48:52aspirin resistanceKranzhofer R 2006Germany2006Prospective cohortCADNANA ITGB3(rs5918) 14: 15aspirin resistanceLepäntalo A 2006Finland2006Prospective cohortPCI61(37–83)75.2 PTGS1(rs10306114) 5:96aspirin resistanceLev EI 2007American2007Prospective cohortPCI65.5 ± 10.968.3 ITGB3(rs5918) 12:108aspirin resistanceLi CX 2011China2011Prospective cohortASCVD61 ± 18.454GPIIIaPLA2, SLC6A9(rs2248829)151:8aspirin resistanceLi X 2019China2019Prospective cohortAIS58.1 ± 10.569.4PTGS1(rs1330344), PTGS2(rs20417)25:45aspirin resistanceLi XG 2017China2017Prospective cohortIS60.5 ± 7.391.4CYP2C19, ABCB128:30aspirin resistanceLi XL 2012China2012Prospective cohortCAD, Stroke, PAOD74.8 ± 8.465.7PTGS1(rs1330344, rs3842787), PTGS2(rs5277)36:230aspirin resistanceLiu J 2023China2023Prospective cohortCAD75.3 ± 328.4 GP IIIa PLA 182:33aspirin resistanceLiu QY 2023China2023Prospective cohortAIS59 ± 5.673.1PTGS2(rs12042763, rs20417)87:125aspirin resistanceLiu SB 2021China2021Prospective cohortAIS61.6 ± 13.265.1 PTGS1 8:290aspirin resistanceLiu Y 2021-1China2021Prospective cohortCAD65.3 ± 9.567.3PEAR1(rs12041331), PTGS1(rs1330344),110:230aspirin resistanceLiu Y 2021-2China2021Prospective cohortCAD65.3 ± 963.4 PTGS2(rs20417) 110:230aspirin resistanceMateos-Cáceres PJ 2008Spain2008Prospective cohortIschemic disease66 ± 859 PTGS1(rs3842787) 19: 19aspirin resistanceMou FQ 2013China2013Prospective cohortIS65.1 ± 15.4NA COX-1 709 C/A 13:14aspirin resistanceMukarram O 2016China2016Prospective cohortCAD58.6 ± 10.868.1ITGA2(rs1126643), ITGB3(rs5918), P2RY1 (rs1065776), PTGS1 (rs3842787)8:32aspirin resistancePamukcu B 2005Turkey2005Prospective cohortCAD56.5 ± 8.977.5 ITGB3(rs5918) 43: 161aspirin resistancePeng LL 2014China2014Prospective cohortStroke62.5 ± 12.662.6PTGS1(rs1330344, rs3842788, rs5788), PTGS2 rs2041718: 174aspirin resistancePeng LL 2016China2016Prospective cohortStroke65.1 ± 12.563.2ABCB1(rs1045642), TBXA2R(rs1131882)33:55aspirin resistanceSevimli S 2014Turkey2014Prospective cohortCAD59.8 ± 775.4 -455 G/A b-fibrinogen 25:89aspirin resistanceSu GH 2007China2007Prospective cohortASCVD65.4 ± 8.374.2 SLC6A9(rs2248829) 9:90aspirin resistanceTIMUR AA 2012American2012Prospective cohortMI, PCI65 ± 1082 P2RY12(rs9859538) 99: 313aspirin resistanceUlehlova J 2014Czech Republic2014Prospective cohortMI5171.2PTGS1(rs10306114), GP1BA(rs2243093), GP6(rs1613662)13:115aspirin resistanceWang BY 2012China2012Prospective cohortCAD, IS76.1 ± 3.665.5 PTGS1(rsl330344) 422:250aspirin resistanceWang H 2018China2018Prospective cohortAIS68 ± 1161.2ITGA2(rs1126643), PTGS2 (rs20417)43:54aspirin resistanceWang L 2015China2015Prospective cohortASCVD69.5 ± 13.474.7PTGS1(rs10306114), P2RY1(rs1065776), SLC6A9(rs2248829)28:144aspirin resistanceWang LQ 2022China2022Prospective cohortCAD69 ± 10.350.8 APOE 37:83aspirin resistanceWang LL 2016China2016Prospective cohortCAD, IS63.2 ± 8.657.3ALOX5AP(rs10507391, rs4769874, rs9551963)340:110aspirin resistanceWang LL 2021China2021Prospective cohortIS63.3 ± 11.372 PTGS1 15:85aspirin resistanceWang XJ 2018China2018Prospective cohortPCI52.5 ± 8.458.5 PEAR1(rs12041331) 105:30aspirin resistanceWang YH 2012China2012Prospective cohortCADNANA PTGS1(rs10306114) 150:6aspirin resistanceWang YM 2012China2012Prospective cohortTreat with antithrombotic therapy68.7 ± 14.876.6 PTGS2(rs20417) 151: 54aspirin resistanceWang ZY 2016China2016Prospective cohortIS63 ± 1157.3ABCB1(rs1045642, rs1128503, rs2032582)77:225aspirin resistanceWen SY 2014China2014Prospective cohortliIS62.1 ± 7.162TbXA2R(rs1131882, rs4523), SLC22A3(rs555754)39:129aspirin resistanceWu SY 2022China2022Prospective cohortAIS66.6 ± 10.169.6GP1BA(rs6065), PEAR1(rs12041331), PTGS1(rs3842788), ITGA2B(rs5911), HMOX1(rs2071746)15:77aspirin resistanceXu L 2021China2021Prospective cohortAIS65 ± 1161.3 CYP2S1(rs34971233) 77:225aspirin resistanceXu LX 2017China2017Prospective cohortIS75.2 ± 8.353.6 PTGS1(rs3842787) 36:180aspirin resistanceXu HN 2021China2021Retrospective cohortAIS60.5 ± 6.554.5 PTGS1 69:131aspirin resistanceXu JJ 2016China2016Prospective cohortCAD58 ± 10.578PTGS1(rs3842788, rs4273915 rs7866582, rs3218625)166:200aspirin resistanceXu X 2013China2013Prospective cohortCAD, IS66.4 ± 12.362CYP2D6(rs72549358), PTGS2(rs20417)89:27aspirin resistanceYang R 2009China2009Prospective cohortCAD, IS68.8 ± 15.678.6PTGS1(rs3842788, rs5788), PTGS2(rs20417)71:110aspirin resistanceYang XF 2020China2020Prospective cohortIS71.5 ± 5.862 GP1BA (rs6065) 12:114aspirin resistanceYe P 2012China2012Prospective cohortCAD65 ± 11NAPTGS1, PTGS2273:95aspirin resistanceYi X 2016China2016Prospective cohortAIS70.4 ± 12.153.5PTGS1(rs1236913, rs3842787), PTGS2(rs689466, rs20417)175:630aspirin resistanceYi XY 2013China2013Prospective cohortIS69.5 ± 10.352.4PTGS1(rs3842787), PTGS2(rs20417)157:477aspirin resistanceYi XY 2016China2016Prospective cohortIS69.6 ± 10.552.3PTGS1(rs1236913, rs3842787), PTGS2(rs20417)157:477aspirin resistanceYi XY 2017China2017Prospective cohortAIS71.1 ± 12.651.7PTGS1(rs1236913, rs3842787), PTGS2(rs689466, rs20417), P2RY1(rs701265, rs1371097)112:717aspirin resistanceYurek E 2023Turkey2023Prospective cohortAIS52.4 ± 13.462.8 ABCB1(MDR-1); C3435T(rs1045642) 174:106aspirin resistanceYu LH 2015China2015Prospective cohortIS70.3 ± 8.576.3 GPIIbHPA-3 152:250aspirin resistanceYuan JG 2016China2016Prospective cohortAIS60.2 ± 10.650.8DE4D (rs966221, rs918592)54:129aspirin resistanceZhang J 2009China2009Prospective cohortCAD75.5 ± 8.261.5 PTGS2(rs20417) 176:23aspirin resistanceZhang SS 2015China2015Retrospective cohortIS64.1 ± 11.964.6PTGS1(rs1330344, rs3842788, rs5788), PTGS2(rs20417)9:87aspirin resistanceZhang WT 2017China2017Prospective cohortAIS59.3 ± 14.173.3ITGB3(rs5918), P2RY1(rs701265, rs1065776)31: 175aspirin resistanceZhang R 2019China2019Prospective cohortAIS62.8 ± 9.953.4 PTGS1(rs10306114) 32:268aspirin resistanceZhao Y 2011China2011Prospective cohortASCVD73.1 ± 6.160.5 PTGS2(rs20417) 73:33aspirin resistanceAbbreviations: AS = Aspirin sensitivity; AR = Aspirin resistance; CAD = coronary artery disease; AIS = Atherosclerotic ischemic stroke; IS = ischemic stroke; MI = myocardial infarction; PCI = percutaneous coronary intervention; PAOD = peripheral arterial occlusive disease; ASCVD = atherosclerotic cardiovascular disease The characteristics of included studies Unstable CAD Abbreviations: AS = Aspirin sensitivity; AR = Aspirin resistance; CAD = coronary artery disease; AIS = Atherosclerotic ischemic stroke; IS = ischemic stroke; MI = myocardial infarction; PCI = percutaneous coronary intervention; PAOD = peripheral arterial occlusive disease; ASCVD = atherosclerotic cardiovascular disease In the included studies, 62 studies (accounting for 82.67%) had NOS scores of 7 or above, indicating that these studies were of high quality. The remaining 13 studies had NOS scores of 6 (Appendix 3). In the included studies, the differences in baseline characteristics between the case group (AR group) and the control group (non-AR group) were the main potential sources of bias. Overall analyses We found a total of 94 gene polymorphisms in the ischemic patients in this study. Of these, 25 genes were consolidated for pooled analysis, and 69 genes were systematically described due to the limited number of studies. Three candidate genes demonstrated a significant correlation with AR. These encompass PTGS2(rs20417), which exhibited an OR of 0.57 (95%CI:0.44–0.73; P<0.001; I2 = 58.8%) (Fig. 2), ITGA2(rs1126643) with an OR of 0.52 (95%CI:0.29–0.93; P = 0.03; I2 = 75.10%) (Fig. 2), TbXA2R(rs1131882) with an OR of 1.54 (95%CI: 1.09–2.18; P = 0.01; I2 = 4.80%) (Appendix 4). Nonetheless, no gene polymorphisms related to AR were observed in the remaining 22 candidate genes (Table 2). Among the meticulously enumerated 69 genes, 20 candidate genes showed potential correlation with AR, among which 10 were P2RY12-related gene loci, all studied in the United States; the remaining 10 candidate genes were primarily studied in China, with 2 of these genes being related to P2RY1 and CYP2C19 gene loci respectively (Appendix 5). Fig. 2Forest plot of (A) PTGS2(rs20417), (B) PTGS1(rs10306114), (C) PTGS1(rs1330344) and (D) ITGA2(rs1126643) Forest plot of (A) PTGS2(rs20417), (B) PTGS1(rs10306114), (C) PTGS1(rs1330344) and (D) ITGA2(rs1126643) Table 2Results of meta analysis for 25 gene polymorphismsGene polymorphismsBase-pairs(Group or subgroup)Studies includedSample sizeP valueOR (95% CI)I2 ABCB1(rs1045642) ARCCCT/TT3790.1860.48(0.16–1.43)89.80%253ASCCCT/TT209357 GP1BA(rs6065) ARCCCT/TT42750.4540.71(0.28–1.76)62.40%59ASCCCT/TT46790 ITGB3(rs5918) ARTTCT/CC73420.241.31(0.83–2.06)7.70%114ASTTCT/CC812172ARA1A1A1A2/A2A231550.570.58(0.09–3.73)18.29%35ASA1A1 A1A2/A2A226961 P2RY1(rs701265) ARAAAG/GG31260.340.68(0.31–1.51)72.00%148ASAAAG/GG435599 PEAR1(rs12041331) ARAAAG/GG42210.243.48(0.44–27.57)82.50%165ASAAAG/GG214236 PTGS1 ARGGAG/AA18< 0.00118.29(4.70,71.13)0.00%7ASGGAG/AA580ARAAAG/GG3450.180.01(0.00-10.22)13.60%32ASAAAG/GG40813 PTGS1(rs10306114) ARAAAG/GG51430.0480.24(0.06–0.99)14.84%20ASAAAG/GG83056ARAAAT/TT11950.930.24(0.06–0.99)0.00%25ASAAAT/TT21328 PTGS1(rs1236913) ARCCCT/TT23520.950.98(0.61–1.59)0.00%25ASCCCT/TT103671 PTGS1(rs1330344) ARAAAG/GG4112< 0.0010.56(0.43–0.74)0.00%289ASAAAG/GG246362ARGGAG/AA200.060.14(0.01–1.06)0.00%27ASGGAG/AA54205ARTTCT/CC31360.621.44(0.35–6.01)92.20%122ASTTCT/CC250351ARTTTG/GG11190.120.75(0.51–1.08)0.00%101ASTTTG/GG14793 PTGS1(rs3842787) ARCCCT/TT54820.280.87(0.68–1.12)0.00%135ASCCCT/TT1453292ARGG GA/AA11980.920.86(0.05–13.85)0.00%1ASGGGA/AA2301 PTGS1(rs3842788) ARGGGA/AA62720.441.39(0.60–3.18)69.90%68ASGGGA/AA837397ARGA22860.120.59(0.31–1.14)0.00%18ASGA51119 PTGS1(rs5788) ARGGGA/AA31550.901.04(0.59–1.84)0.00%17ASGGGA/AA66568ARCA22740.010.51(0.30–0.87)0.00%30ASCA50228 PTGS2(rs20417) ARGGGC/CC181362< 0.0010.61(0.48–0.79)56.20%461ASGGGC/CC3314914ARGC21079< 0.0010.23(0.11–0.52)0.00%440ASGC2793905 PTGS2(rs5277) ARGGGC/CC22360.080.54(0.28–1.07)85.40%22ASGGGC/CC30615 PTGS2(rs689466) ARTTCT/CC21770.390.58(0.16–2.03)89.00%103ASTTCT/CC222109ARAAAG/GG41490.101.33(0.95–1.87)48.70%377ASAAAG/GG3571098 ITGA2(rs1126643) ARCCTC/TC61000.030.52(0.29–0.94)75.10%200ASCCTC/TC450556 ITGB3(rs2317676) ARAAAG/GG2820.240.81(0.56–1.16)0.00%58ASAAAG/GG711411 ITGB3(rs11871251) ARAAAG/GG2500.141.32(0.91–1.92)36.80%90ASAAAG/GG313809 P2RY1(rs1065776) ARCCTC/TC41740.340.69(0.32–1.48)54.00%29ASCCTC/TC73885 TbXA2R(rs1131882) ARCCTC/TC31960.011.54(1.09–2.18)4.80%96AS CCCTC/TC334286 ITGA2B(rs5911) ARAAAC/CC2190.060.57(0.31–21.03)85.10%47ASAAAC/CC99134 TbXA2R(rs4523) ARTTCT/CC3750.351.58(0.61–4.10)77.00%207ASTTCT/CC229366 GP1BA(rs2243093) ARTTCT/CC32380.271.27(0.83–1.94)45.90%106ASTTCT/CC487338 GP6(rs1613662) ARCCCT/TT2170.770.72(0.08–6.40)85.40%22ASCCCT/TT80104 HMOX1(rs2071746) ARAAAT/TT2890.240.79(0.54,1.17)25.70%192ASAAAT/TT77162ARAAAC/CC1570.260.79(0.53,1.19)0.00%163ASAAAC/CC74167 Table 2Results of meta analysis for 25 gene polymorphismsGene polymorphismsBase-pairs(Group or subgroup)Studies includedSample sizeP valueOR (95% CI)I2 ABCB1(rs1045642) ARCCCT/TT3790.1860.48(0.16–1.43)89.80%253ASCCCT/TT209357 GP1BA(rs6065) ARCCCT/TT42750.4540.71(0.28–1.76)62.40%59ASCCCT/TT46790 ITGB3(rs5918) ARTTCT/CC73420.241.31(0.83–2.06)7.70%114ASTTCT/CC812172ARA1A1A1A2/A2A231550.570.58(0.09–3.73)18.29%35ASA1A1 A1A2/A2A226961 P2RY1(rs701265) ARAAAG/GG31260.340.68(0.31–1.51)72.00%148ASAAAG/GG435599 PEAR1(rs12041331) ARAAAG/GG42210.243.48(0.44–27.57)82.50%165ASAAAG/GG214236 PTGS1 ARGGAG/AA18< 0.00118.29(4.70,71.13)0.00%7ASGGAG/AA580ARAAAG/GG3450.180.01(0.00-10.22)13.60%32ASAAAG/GG40813 PTGS1(rs10306114) ARAAAG/GG51430.0480.24(0.06–0.99)14.84%20ASAAAG/GG83056ARAAAT/TT11950.930.24(0.06–0.99)0.00%25ASAAAT/TT21328 PTGS1(rs1236913) ARCCCT/TT23520.950.98(0.61–1.59)0.00%25ASCCCT/TT103671 PTGS1(rs1330344) ARAAAG/GG4112< 0.0010.56(0.43–0.74)0.00%289ASAAAG/GG246362ARGGAG/AA200.060.14(0.01–1.06)0.00%27ASGGAG/AA54205ARTTCT/CC31360.621.44(0.35–6.01)92.20%122ASTTCT/CC250351ARTTTG/GG11190.120.75(0.51–1.08)0.00%101ASTTTG/GG14793 PTGS1(rs3842787) ARCCCT/TT54820.280.87(0.68–1.12)0.00%135ASCCCT/TT1453292ARGG GA/AA11980.920.86(0.05–13.85)0.00%1ASGGGA/AA2301 PTGS1(rs3842788) ARGGGA/AA62720.441.39(0.60–3.18)69.90%68ASGGGA/AA837397ARGA22860.120.59(0.31–1.14)0.00%18ASGA51119 PTGS1(rs5788) ARGGGA/AA31550.901.04(0.59–1.84)0.00%17ASGGGA/AA66568ARCA22740.010.51(0.30–0.87)0.00%30ASCA50228 PTGS2(rs20417) ARGGGC/CC181362< 0.0010.61(0.48–0.79)56.20%461ASGGGC/CC3314914ARGC21079< 0.0010.23(0.11–0.52)0.00%440ASGC2793905 PTGS2(rs5277) ARGGGC/CC22360.080.54(0.28–1.07)85.40%22ASGGGC/CC30615 PTGS2(rs689466) ARTTCT/CC21770.390.58(0.16–2.03)89.00%103ASTTCT/CC222109ARAAAG/GG41490.101.33(0.95–1.87)48.70%377ASAAAG/GG3571098 ITGA2(rs1126643) ARCCTC/TC61000.030.52(0.29–0.94)75.10%200ASCCTC/TC450556 ITGB3(rs2317676) ARAAAG/GG2820.240.81(0.56–1.16)0.00%58ASAAAG/GG711411 ITGB3(rs11871251) ARAAAG/GG2500.141.32(0.91–1.92)36.80%90ASAAAG/GG313809 P2RY1(rs1065776) ARCCTC/TC41740.340.69(0.32–1.48)54.00%29ASCCTC/TC73885 TbXA2R(rs1131882) ARCCTC/TC31960.011.54(1.09–2.18)4.80%96AS CCCTC/TC334286 ITGA2B(rs5911) ARAAAC/CC2190.060.57(0.31–21.03)85.10%47ASAAAC/CC99134 TbXA2R(rs4523) ARTTCT/CC3750.351.58(0.61–4.10)77.00%207ASTTCT/CC229366 GP1BA(rs2243093) ARTTCT/CC32380.271.27(0.83–1.94)45.90%106ASTTCT/CC487338 GP6(rs1613662) ARCCCT/TT2170.770.72(0.08–6.40)85.40%22ASCCCT/TT80104 HMOX1(rs2071746) ARAAAT/TT2890.240.79(0.54,1.17)25.70%192ASAAAT/TT77162ARAAAC/CC1570.260.79(0.53,1.19)0.00%163ASAAAC/CC74167 Results of meta analysis for 25 gene polymorphisms CC CT/TT CC CT/TT CC CT/TT CC CT/TT TT CT/CC TT CT/CC A1A1 A1A2/A2A2 AA AG/GG AA AG/GG AA AG/GG AA AG/GG GG AG/AA GG AG/AA AA AG/GG AA AG/GG AA AG/GG AA AG/GG AA AT/TT AA AT/TT CC CT/TT CC CT/TT AA AG/GG AA AG/GG GG AG/AA GG AG/AA TT CT/CC TT CT/CC TT TG/GG TT TG/GG CC CT/TT CC CT/TT GG GA/AA GG GA/AA GG GA/AA G A G A GG GA/AA GG GA/AA C A C A GG GC/CC GG GC/CC G C G C GG GC/CC GG GC/CC TT CT/CC TT CT/CC AA AG/GG AA AG/GG CC TC/TC CC TC/TC AA AG/GG AA AG/GG AA AG/GG AA AG/GG CC TC/TC CC TC/TC CC TC/TC CC TC/TC AA AC/CC AA AC/CC TT CT/CC TT CT/CC TT CT/CC TT CT/CC CC CT/TT CC CT/TT AA AT/TT AA AT/TT AA AC/CC AA AC/CC Subgroup analyses Further subgroup analyses were conducted based on gene polymorphisms. Our findings reveal that for PTGS1(rs1330344), the AA genotype is associated with a reduced risk compared to AG/GG (OR = 0.56; 95%CI: 0.43–0.74; P < 0.001; I2 = 0.00%), as detailed in Appendix 4. Similarly, for PTGS1(rs5788), the C allele demonstrates a protective effect against the A allele (OR = 0.51; 95%CI: 0.30–0.87; P = 0.013; I2 = 0.00%), also presented in Appendix 4. However, other subgroup analyses based on gene polymorphisms did not yield statistically significant differences, as summarized in Table 2 and Appendix 4. Subgroup analyses conducted across various research regions have indicated that certain genetic polymorphism, including P2RY1(rs701265), PTGS1, PTGS1(rs1236913), PTGS1(rs3842788), PTGS1(rs5788), PTGS2(rs5277), PTGS2(rs689466), ITGA2(rs1126643), ITGB3(rs2317676), ITGB3(rs11871251), ITGA2B(rs5911), TbXA2R(rs4523), and PTGS1(rs1330344) AA vs. AG/GG, have only been investigated in Asia so far. Among these, ITGA2(rs1126643), the PTGS1 GG vs. AG/AA genotype, PTGS1(rs5788) C vs. A genotype, and PTGS1(rs1330344) AA vs. AG/GG have been found to be significantly correlated with AR. In contrast, GP6(rs1613662) has been the subject of study exclusively in Europea and does not exhibit a significant association with AR (appendix 6). Other genetic polymorphism have been examined in multiple regions, encompassing Asia, Europe, Africa, and North America. For instance, ABCB1(rs1045642) and GP1BA(rs2243093) have been significantly linked to AR in Asia but not in Europea. ITGB3(rs5918) demonstrates a significant correlation with AR in Africa, yet not in Asia or Europea. PTGS1(rs10306114) is significantly associated with AR in Europea but not in Asia. P2RY1(rs1065776) is associated with AR in North America, specifically the United States, but not in Asia. PTGS2(rs20417) is significantly correlated with AR in both Asia and Europea, whereas TbXA2R(rs1131882) and PTGS1(rs1330344) TT vs. CT/CC are not significantly associated with AR in either Asia or Europea. The details of the subgroup analysis are shown in appendix 6. In a subgroup analysis of patient disease, individuals with the PTGS1(rs5788) variant who experienced an ischemic stroke (OR = 0.98, 95%CI: 0.54–1.67) may exhibit an elevated risk of AR compared to those with coronary artery disease (OR = 0.51, 95%CI: 0.3–0.87) (Fig. 3). Fig. 3Forest plot of subgroup analyses Forest plot of subgroup analyses Sensitivity analysis Sensitivity analyses were conducted by excluding one study at a time, provided the initial analyses encompassed a minimum of five studies. No alterations in the outcomes were observed for the gene polymorphisms under investigation across all comparisons, suggesting that our results are statistically robust. Publication bias Based on the contour-enhanced funnel plot analysis, no discernible asymmetry in the funnel plots was noted in any of the comparisons, indicating that our meta-analysis is unlikely to have been significantly influenced by evident publication bias (Appendix 7). Discussion Aspirin is commonly prescribed to prevent CVD. Its efficacy in lowering major adverse cardiovascular events has been well established [3]. It is not uncommon for AR to affect the efficacy of treatment in patients [12, 13]. Understanding genetic profiles of AR in ischemic patients on aspirin is crucial for identifying high-risk individuals and optimizing anti-platelet therapy for CVD patients to improve prognosis [17, 108]. Pharmacogenomics, which involves using genomic information to tailor drug management, is a strategy to maximize drug efficacy and minimize toxicity [109]. Therefore, Many studies have actively explored gene polymorphisms related to AR. This study included relevant published research and used a meta-analysis approach to investigate the correlation between AR and candidate genes. The findings are as follows: Currently, 95 candidate genes have been studied associated with AR in patients with cardiovascular and cerebrovascular diseases, among which 25 candidate genes have been studied in more than one study. The distribution of 25 candidate genes also shows significant regional differences. Thirteen candidate genes have only been studied in Asia, while the GP6 (rs1613662) gene has only been studied in Europe, and other candidate genes have been researched in multiple countries. The difference in candidate gene across different regions is related to the differences in the distribution of gene polymorphisms among races, such as the CYP2C19 gene polymorphism, which has significant racial and geographical differences, with the mutation in Asians being about 3–4 times that of Caucasians [30]. This study found that PTGS2 (rs20417), ITGA2 (rs1126643), and TbXA2R (rs1131882) are significantly correlated with AR. Subgroup analysis showed that PTGS2 (rs20417) is significantly correlated with AR in both Asia and Europe. The analysis results in Asia were based on the combined data of 17 studies, with a total sample size of 4756, and the heterogeneity was acceptable, thus the results are relatively reliable. The analysis results in Europe were based on data from one study in Russia, and still require validation from large-sample, high-quality studies. This study included 7 candidate genes related to PTGS2, with the other six candidate genes being rs5277, rs689466, rs68946, rs5275, rs3218625, and rs689465. The first two candidate genes did not show statistical differences when combined for analysis, while the last four candidate genes could not be combined for analysis due to only one study being available. rs689465 showed a significant association with AR. PTGS2 encodes an inducible isozyme that may affect the biological effects of prostaglandins derived from COX-2, participates in regulating platelet aggregation, and is also a target of aspirin. Therefore, mutations in PTGS2(rs20417) may increase the risk of AR [93]. Consistent with this finding, Weng ZY’s research, through subgroup analysis and multivariate regression models, also found a significant correlation between PTGS2(rs20417) and AR [23]. ITGA2 (rs1126643) has only been studied in Asia, and therefore can only be said to be significantly associated with AR in Asia. The results are based on the combined data of six studies, which had considerable heterogeneity, and the interpretation of the results should be cautious. One study reported that the average frequency of the ITGA2 gene rs1126643-T allele was 40.77% in Caucasian patients with AR, but was as high as 58.58% in Chinese patients [23]. Another candidate gene from the ITGA2 gene family included in this study is rs1062535, which was studied in Russia and showed no significant correlation with AR. This gene encodes the alpha subunit of a transmembrane receptor, mediating the adhesion of platelets to the extracellular matrix. Therefore, mutations in this gene may also be associated with AR [110]. Subgroup analysis indicated that TbXA2R(rs1131882) was not significantly associated with AR in either Asia or Europea, which differs from the overall analysis results, mainly due to the smaller sample size in the subgroup analysis. This study also involved other TbXA2R candidate genes, including rs4523, rs2271875, rs768963, G1686A, rs2238630, rs2238631, rs2238633, rs3786989. Only a few studies were combined for analysis, and the results showed that these candidate genes were not significantly associated with AR. Therefor, future research is expected to continue to verify these results. TBXA2R encodes the specific receptor for TXA2, thereby inducing platelet activation and aggregation, thus mutations in TBXA2R may be associated with AR [68]. The results of studies on ABCB1(rs1045642) and GP1BA(rs2243093) as well as PTGS1(rs10306114) are inconsistent across different regions. On one hand, this could be due to the inclusion of fewer subgroup studies, which may not produce statistically significant differences due to small sample sizes. On the other hand, it could also be attributed to genetic differences among different ethnic groups. Other candidate genes include ABCB1 (rs1045642), GP1BA (rs2243093), and PTGS1 (rs10306114), among others, which are primarily various targets on the pathways of platelet activation and aggregation. These genes have shown inconsistent results across different regions. On one hand, this could be due to the inclusion of fewer studies in subgroup analyses, which may result in a lack of statistical significance due to small sample sizes. On the other hand, it could also be attributed to genetic differences among different ethnics. This study included patients with ischemic diseases such as coronary heart disease and stroke, with treatment regimens including single antiplatelet therapy and dual antiplatelet therapy, which could all be sources of heterogeneity. It is important to note that despite extensive investigation, the reasons why patients with ischemic diseases develop AR remain unclear, and it is therefore unlikely that a single gene polymorphism significantly contributes to the occurrence and development of this phenomenon. Consequently, we may need to identify a group of genes at increased risk of AR and related cardiovascular events in ischemic disease patients by considering relevant genetic biomarkers in combination. Our meta-analysis undeniably possesses limitations. Firstly, although the included cohort studies mainly consisted of elderly and male participants, the meta-analysis failed to deeply explore the differences in age and gender due to insufficient data. Secondly, the relationship between specific gene polymorphisms and AR in ischemic disease patients may be intricately influenced by gene-gene and gene-environmental interactions. However, due to a lack of relevant data, we did not analyze the effects of these interactions in the present meta-analysis. Thirdly, It is also noteworthy that in the current study, the sample size of some candidate genes (e.g., PTGS1) compared is limited, which may not be sufficient to detect the actual correlation between certain genetic polymorphisms and AR in patients with ischemic diseases. Therefore, the results need to be interpreted with caution. It is crucial to have larger-scale, well-designed studies to produce more reliable findings. Conclusions In conclusion, Our meta-analysis suggests that PTGS2 (rs20417), ITGA2 (rs1126643), and TbXA2R (rs1131882) gene polymorphisms may serve as promising genetic biomarkers for AR. Considering the number of studies included, sample size, and heterogeneity, PTGS2 (rs20417) is recommended as a genetic biomarkers for patients with ischemic diseases in the Asian region before taking aspirin, with the GC/CC genotype increasing the risk of AR by 42% compared to the GG genotype. However, it is not recommended for the European population at this time. ITGA2 (rs1126643) increases the risk of AR by 48% in the Asian region for the TC/TC genotype compared to the CC genotype. Candidate genes such as ABCB1(rs1045642) and GP1BA(rs2243093) show inconsistent risks associated with AR in different regions, and further validation of these results is expected from large-scale, high-quality studies. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1